Zhang, Ling

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 465

XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Kruer, T. L., Quintana, A., Ferrall-Fairbanks, M., Zhang, L., Newman, H., McLemore, A. F., Yang, Q., Bencrentsil, N., Komrokji, R. S., Chaudhry, S., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 8